

Patient Information	Specimen Information	Client Information
LastName, FirstName DOB: 08/01/1956 AGE: 57 Gender: M Phone: 800.555.1212 Patient ID: 12345	Specimen: ST1_90666_2 Requisition: 1234567 Collected: 01/12/2014 / 10:48 PST Received: 01/06/2014 / 15:40 PST Reported: 01/13/2014 / 08:41 PST	Client #: 97502840 1234567 COLMENAR, ANTONIO B TEST CLIENT (NAME) Attn: TEST DEPARTMENT 1201 S COLLEGEVILLE RD COLLEGEVILLE, PA 19426

HIV 1 CORECEPTOR TROPISM
Lab: EZ

Test Name	Results	Reference Range
VALUE OF LAST VIRAL LOAD	1496	copies/mL
DATE VIRAL LOAD COLLECTED	10/18/2013	
CXCR4(X4)	NOT DETECTED	

ULTRADEEP SEQUENCING
Lab: EZ

Test Name	Results	Reference Range
UDS X4	DETECTED	

INTERPRETATION
Lab: EZ

Test Name	Results	Reference Range
NET TROPISM ASSESSMENT	DM/X4	
MVC ACTIVITY ANTICIPATED	NO	

UDS: Ultra Deep Sequencing MVC: Maraviroc (Selzentry) DM: Dual-Mixed

A Net Tropism Assessment of "R5" indicates that only R5 virus was detected in this sample. A Net Tropism Assessment of "DM/X4" indicates that Dual-Mixed or X4 virus was detected in this sample.

This test utilizes RT-PCR and DNA sequencing performed in triplicate to detect the presence of HIV-1 envelope V3 loop variants associated with CXCR4 (X4) coreceptor utilization.

If X4 virus is not detected by population sequencing, UDS is performed to more sensitively detect minority X4 virus. This assay will report X4 if found in 2% or more of the UDS reads. The use of CCR5 coreceptor antagonists to treat HIV-1 is not recommended for patients harboring X4-tropic virus.

In viral mixtures of X4 virus in an R5 background at 25,000 copies/mL, X4 was detected by population sequencing in 95% of samples with 20% X4. UDS detected 95% of samples with 12% X4 at a viral load of 25,000 cp/mL and with 5% X4 at a viral load of 100,000 cp/mL.

This assay successfully amplified HIV-1 subtypes A, B, C, D, AG, and H, but failed to adequately amplify subtypes AE, F and G for tropism determination. Less data are available for tropism of non-B subtypes and tropism determination for these subtypes may be associated with a greater degree of uncertainty.

This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. Performance characteristics refer to the analytical performance of the test.

<http://education.questdiagnostics.com/faq/FAQ86>

PERFORMING SITE:

EZ QUEST DIAGNOSTICS/NICHOLS SJC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: JON NAKAMOTO, MD PHD, CLIA: 05D0643352